ANI Pharmaceuticals
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
3/10
|
51.77 | 57.88 | -10.56% | 61.24 | -15.48% |
| P/S |
|
2 | 4.07 | -50.91% |
|
|
| P/BV |
|
2.25 | 9.4 | -76.09% |
|
|
| P/FCF |
|
12.05 | 46.57 | -74.13% |
|
|
| Ev/Ebitda |
|
9.75 | 17.62 | -44.65% |
|
|
| Ev/S |
|
2.19 | 4.37 | -49.87% |
|
|
| Ev/FCF |
|
10.62 | 54.59 | -80.56% |
|
|
| E/P |
|
0.0155 | 0.2164 | -92.84% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
7/10
|
22.46 | 20.15 | 11.46% | 16.84 | +33.32% |
| ROE |
|
4.34 | -80.86 | -105.37% |
|
|
| ROA |
|
2.08 | 6.71 | -69.07% |
|
|
| ROIC |
|
0 | 15.68 | -100% |
|
|
| ROS |
|
3.86 | 10.55 | -63.43% |
|
|
| ROCE |
|
11.45 | 18.05 | -36.6% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
5/10
|
2.61 | 2.87 | -9.05% | 2.77 | -5.75% |
| Nеt Debt/Ebitda |
|
0.8618 | 3.69 | -76.67% |
|
|
| Debt/Ratio |
|
0.3159 | 0.261 | 21.02% |
|
|
| Debt/Equity |
|
6.61 | 4.49 | 47.13% |
|
|
| Debt/Net Income |
|
15.21 | 6.45 | 135.79% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 1.31 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 6.33 | -100% | ||
| DSI |
|
0 | 0.7376 | -100% |
|
|
| Average dividend growth |
|
0 | -3.12 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 1.29 | -100% |
|
|
| Average percentage for payments |
|
4.33 | 77.61 | -94.42% |
|
|
| Difference from average difference in sector |
|
-1.31 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
135.69 | 362.86 | -62.61% | ||
| Growth impulse Ebitda in 5 years |
|
75.52 | 373.75 | -79.79% | ||
| Growth impulse Net Income in 5 years |
|
208.16 | 454.84 | -54.23% | ||
| Growth impulse FCF in 5 years |
|
455.51 | 306.17 | 48.78% | ||
| Growth impulse EPS in 5 years |
|
103.92 | 455.99 | -77.21% |
IP Score
4.89/10
